PsO Studies N=5181 | PsA Studies N=1380 | AS Studies N=794 | |
Median exposure (min–max), days | 505.0 (1–1825) | 1067.5 (8–1827) | 981.5 (1–1530) |
Total exposure, PY | 10 416.9 | 3866.9 | 1943.1 |
Incidence, identified by standard definition (preferred term) | |||
CD, EAIR per 100 PY (95% CI) | 0.05 (0.02 to 0.11) | 0.08 (0.02 to 0.23) | 0.4 (0.2 to 0.8) |
UC, EAIR per 100 PY (95% CI) | 0.13 (0.07 to 0.23) | 0.08 (0.02 to 0.23) | 0.2 (0.1 to 0.5) |
IBDU, EAIR per 100 PY (95% CI) | 0.01 (0.00 to 0.05) | 0.05 (0.01 to 0.19) | 0.1 (0.0 to 0.3) |
EAIR data are displayed to two decimals where N>1000; if N<1000, then data are displayed to one decimal.
AS, ankylosing spondylitis; CD, Crohn’s disease; EAIR, exposure-adjusted incidence rate; IBD, inflammatory bowel disease; IBDU, IBD-unclassified; PY, patient-years; PsA, psoriatic arthritis; PsO, psoriasis; UC, ulcerative colitis.